44 assets in Head And Neck Carcinoma

Therapeutic assets addressing Head And Neck Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	BB (70)
Pembrolizumab Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	BB (66)
Nivolumab Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	B (60)
Binimetinib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Capivasertib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Crizotinib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Dabrafenib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Dasatinib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Defactinib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Fexagratinib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Gsk-2636771 Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Osimertinib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Palbociclib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pertuzumab Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Rain-32 Head And Neck Carcinoma	Rain Oncology Inc	P2	CCC (53)
Relatlimab Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Sapanisertib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trametinib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Vismodegib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Adavosertib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Taselisib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Copanlisib Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (49)
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Head And Neck Carcinoma	Natalie Lockney	P1/2	CCC (48)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- Head And Neck Carcinoma	VM Oncology, LLC	P1/2	CCC (48)
Docetaxel Head And Neck Carcinoma	OncoC4, Inc.	P1/2	CCC (48)
Gabapentin Head And Neck Carcinoma	Natalie Lockney	P1/2	CCC (48)
Gotistobart Head And Neck Carcinoma	OncoC4, Inc.	P1/2	CCC (48)
Valemetostat Head And Neck Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Cabozantinib Head And Neck Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Cis-Diamminedichloroplatinum Ii Head And Neck Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Elimusertib Head And Neck Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Fludeoxyglucose Head And Neck Carcinoma	Jonsson Comprehensive Cancer Center	P1	CC (43)
Immunoglobulin G1 [De-236-Glycine,267-Glutamic Acid,De-C-Terminal Lysine], Anti-(Human Tumor Necrosis Factor Receptor Tnfrsf9) (Human-Mus Musculus Monoclonal Lvgn6051 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Lvgn6051 ?-Chain, Dimer Head And Neck Carcinoma	M.D. Anderson Cancer Center	P1	CC (43)
Immunoglobulin G1 [De-236-Glycine,De-C-Terminal Lysine], Anti-(Human Cd40 Antigen) (Human Monoclonal Lvgn7409 ?1-Chain), Disulfide With Human Monoclonal Lvgn7409 ?-Chain, Dimer Head And Neck Carcinoma	M.D. Anderson Cancer Center	P1	CC (43)
Pradusinstobart Head And Neck Carcinoma	M.D. Anderson Cancer Center	P1	CC (43)
Calendula Head And Neck Carcinoma	OHSU Knight Cancer Institute	N/A	D (30)
Hydrocortisone Head And Neck Carcinoma	OHSU Knight Cancer Institute	N/A	D (30)
Sulfadiazine Head And Neck Carcinoma	OHSU Knight Cancer Institute	N/A	D (30)